A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Inclusion Criteria:

• Signed informed consent form

• 18 years of age or older

• Documented diagnosis of ulcerative colitis (UC) at least 12 weeks prior to screening

• Moderately to severely active UC as per the modified Mayo score

• Demonstrated inadequate response to or intolerance of conventional therapy and/oradvanced therapy as defined in the protocol

Exclusion Criteria:

• Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, orCrohn's disease

• Surgery within 8 weeks before screening or planned surgery during the study that mayconfound the evaluation of benefit from study intervention

• Receiving prohibited medications and treatments

• UC limited to the rectum only

• Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) corona virusdisease (COVID-19) infection